Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00543751
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this study is to compare how MK0767 and metformin and sulfonylurea therapy lower blood glucose in patients with inadequate glycemic control This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Primary Completion: 2003-11
• Study Completion: 2003-11
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-16
• Last Update Posted: 2015-06-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 610

Inclusion Criteria

• Patients with Type 2 diabetes wtih inadequate glycemic control on maximally effective/tolerated metformin and sulfonylurea therapy
• Non-pregnant females

Read More

Exclusion Criteria

• Patients with Type 1 Diabetes or history of ketoacidosis
• Patients who have been treated with insulin or other antihyperglycemic agents
• Patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, HIV positive, history hematologic disorders or neoplastic disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL